The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AVIDITY BIOSCIENCES INC COM 05370A108   8,108,000 200,000 SH   SOLE   200,000 0 0
CORBUS PHARMACEUTICALS HLDGS COM NEW 21833P301   14,267,143 325,140 SH   SOLE   325,140 0 0
CYTOKINETICS INC COM NEW 23282W605   246,073,509 4,575,558 SH   SOLE   4,575,558 0 0
ELEVATION ONCOLOGY INC COM 28623U101   4,809,888 1,916,290 SH   SOLE   1,916,290 0 0
GERON CORP COM 374163103   106,184,731 23,915,480 SH   SOLE   23,915,480 0 0
INSMED INC COM PAR $.01 457669307   237,076,310 3,541,095 SH   SOLE   3,541,095 0 0
KEROS THERAPEUTICS INC COM 492327101   68,772,403 1,525,902 SH   SOLE   1,525,902 0 0
SPYRE THERAPEUTICS INC COM NEW 00773J202   10,265,828 452,040 SH   SOLE   452,040 0 0
VAXCYTE INC COM 92243G108   163,916,116 2,080,946 SH   SOLE   2,080,946 0 0